Recursion Pharmaceuticals
Builds investigational medicines through automated biology, AI chemistry, and partner programs.
$3.35
After-hours close+0.02 (+0.60%)
At close$3.33(−3.20%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 70.05%367.56M sharesInsiders 3.42%17.96M sharesOther 26.53%139.16M shares
Shares outstanding 524.68M · Float 408.73M · 77.9% free float
Institutions13F, as of Jun 30, 2026
359 holders · 367.56M shares · 55 new positions · 188 increased · 98 reduced · 46 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 50.30M | 9.59% | +7.11M | Aug 7, 2026 |
| Ark Investment Management LLC | 41.34M | 7.88% | +1.12M | Aug 14, 2026 |
| State Street Corp | 34.71M | 6.61% | +6.22M | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 31.13M | 5.93% | +8.37M | Aug 13, 2026 |
| Baillie Gifford & Co | 23.49M | 4.48% | −187.5K | Aug 6, 2026 |
| Vanguard Capital Management LLC | 22.77M | 4.34% | +521.6K | Aug 13, 2026 |
| Geode Capital Management, LLC | 13.82M | 2.63% | +1.54M | Aug 12, 2026 |
| SoftBank Group Corp. | 13.64M | 2.60% | 0 | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| ARK Investment Management LLC | 7.25% | 37.32M | 13G | Feb 3, 2026 ↗ |
| BlackRock, Inc. | 7.20% | 37.82M | 13G | Apr 24, 2026 ↗ |
| State Street Corporation | 6.60% | 34.71M | 13G | Aug 7, 2026 ↗ |
| Baillie Gifford & Co | 6.50% | 24.86M | 13G | Feb 12, 2025 ↗ |
| Vanguard Portfolio Management | 5.97% | 31.37M | 13G | Jul 31, 2026 ↗ |
| Vanguard Capital Management | 5.09% | 26.74M | 13G | Jul 31, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Blake Borgeson | director | 6.19M | 1.18% | Aug 6, 2026 |
| Christopher Gibson | director | 5.20M | 0.99% | Jun 5, 2026 |
| Najat Khan | director, officer: CEO and President | 2.10M | 0.40% | Aug 18, 2026 |
| Dean Y. Li | director | 1.47M | 0.28% | Jul 2, 2026 |
| Ben R. Taylor | officer: Chief Financial Officer | 1.08M | 0.21% | Aug 18, 2026 |
| David Hallett | officer: Chief Scientific Officer | 1.04M | 0.20% | Aug 18, 2026 |
| Zavain Dar | director | 240.8K | 0.05% | Jul 2, 2026 |
| Franziska Michor | director | 215.5K | 0.04% | Jun 22, 2026 |
| Robert Hershberg | director | 162.2K | 0.03% | Jun 22, 2026 |
| Elaine D. Sun | director | 136.0K | 0.03% | Jun 22, 2026 |
5 ten-percent owners hold 32.51M shares by Form 4, outside the officers-and-directors figure above · 8 people have not refiled in the last 18 months (2.62M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 4, 2026 | Blake Borgesondirector | Sale | 30,000 | $3.25 | 6,188,287 |
| Jul 7, 2026 | Blake Borgesondirector | Sale | 40,000 | $3.96 | 6,218,287 |
| Jun 18, 2026 | Namandje Bumpusdirector | Sale | 3,963 | $3.18 | 127,632 |
| Jun 5, 2026 | Najat Khandirector, officer: CEO and President | Sale | 23,588 | $3.58 | 2,175,796 |
| Jun 5, 2026 | Christopher Gibsondirector | Sale | 40,000 | $3.62 | 883,735 |
| Jun 2, 2026 | Blake Borgesondirector | Sale | 30,000 | $3.68 | 6,169,863 |
| Jun 3, 2026 | Namandje Bumpusdirector | Sale | 4,386 | $3.54 | 43,171 |
| May 22, 2026 | Christopher Gibsondirector | Sale | 40,000 | $3.08 | 883,735 |
| May 7, 2026 | Christopher Gibsondirector | Sale | 40,000 | $3.37 | 926,556 |
| May 5, 2026 | Blake Borgesondirector | Sale | 30,000 | $3.52 | 6,199,863 |
CongressHouse and Senate disclosures
Not reported.